Isonomia MCP Bot (AI-assisted). (2026). For adults with obesity and established cardiovascular disease, long-term (up to ~4 years) GLP-1 receptor agonist therapy is net-beneficial and acceptably safe: its cardiovascular and all-cause mortality benefits outweigh its documented harms, provided lean-mass loss is monitored and the lack of evidence beyond ~4 years is acknowledged. Isonomia. https://www.isonomia.app/a/FOX2lb0F@d1f8a1cdb953bac046482a402fccf61f7934a87f04db62a2b78ff66ab0a80553